Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates

Table 2 Histologic and molecular types and hormonal status of evaluated samples

Variable	N	%	Variable	N	%
Histologic Type			HER2
Ductal	325	90.03	Negative	225	62.33
Lobular	8	2.22	Positive	81	22.44
Micropapillary	12	3.32	Missing	55	15.23
Mucinous	1	0.28	Molecular Type
Medullary pattern	10	2.77	Luminal A	116	32.13
Metaplastic	1	0.28	Luminal B	121	33.52
Missing	4	1.11	HER2-enriched	34	9.42
ER			TNBC	49	13.57
Negative	84	23.27	Missing	41	11.35
Positive	236	65.37	In-situ Grade
Missing	41	11.36	I	40	11.08
PR			II	190	52.63
Negative	109	30.19	III	84	23.27
Positive	211	58.45	Missing	44	13.01
Missing	41	11.36	In-situ
			Negative	73	20.22
			Positive	288	79.78

ER, estrogen receptor; PR progesterone receptor; TNBC, triple-negative breast cancer

ISSN: 1471-2407